**Name of Journal:** *World Journal of Methodology*

**Manuscript NO:** 84619

**Manuscript Type:** REVIEW

**Evolving utility of exosomes in pancreatic cancer management**

Anoop TM *et al*. Role of exosomes in pancreatic cancer

Thattungal Manoharan Anoop, Palash Kumar Basu, K Chandramohan, Ajai Thomas, S Manoj

**Thattungal Manoharan Anoop, Ajai Thomas, S Manoj,** Department of Medical Oncology, Regional Cancer Center, Medical College Campus, Thiruvananthapuram 695011, Kerala, India

**Palash Kumar Basu,** Department of Avionics, Indian Institute of Space Science & Technology (IIST), Thiruvananthapuram 695547, Kerala, India

**K Chandramohan,** Surgical Oncology, Regional Cancer Center, Thiruvananthapuram 695011, Kerala, India

**Author contributions:** Anoop TM designed the study, drafted the manuscript; Basu PK participated in the design and draft of the manuscript; Chandramohan K participated in the design and draft of the manuscript; Thomas A participated in the design and draft of the manuscript; Manoj S participated in the design and draft of the manuscript.

**Corresponding author: Thattungal Manoharan Anoop, MBBS, MD, DM, DNB, FRCP Edin, Associate Professor,** Department of Medical Oncology, Regional Cancer Center, Medical College Campus, Kumarapuram Road, Thiruvananthapuram 695011, Kerala, India. dranooptm@yahoo.co.in

**Received:** March 22, 2023

**Revised:** May 2, 2023

**Accepted:** May 31, 2023

**Published online:**

**Abstract**

Despite the development of newer oncological treatment, the survival of patients with pancreatic cancer (PC) remains poor. Recent studies have identified exosomes as essential mediators of intercellular communications and play a vital role in tumor initiation, metastasis and chemoresistance. Thus, the utility of liquid biopsies using exosomes in PC management can be used for early detection, diagnosis, monitoring as well as drug delivery vehicles for cancer therapy.This review summarizes the function, and clinical applications of exosomes in cancers as minimally invasive liquid biomarker in diagnostic, prognostic and therapeutic roles.

**Key Words:** Pancreatic cancer; Exosomes; Biomarker; Liquid biopsy; Clinical applications; Circulating biomarkers

Anoop TM, Basu PK, Chandramohan K, Thomas A, Manoj S. Evolving utility of exosomes in pancreatic cancer management. *World J Methodol* 2023; In press

**Core Tip:** The determination and identification of biomarkers using liquid biopsy can enable the early detection, monitoring, therapeutic interventions, risk of relapse, therapeutic targets and identification of resistance mechanisms in pancreatic cancer (PC). There has been a recent interest in use of exosomes as biomarker in PC management. Exosomes loaded with multiple diagnostic molecules can be isolated from different body fluids and can be used for making the exosome markers-based liquid biopsy more attractive for initial tumor detection, monitoring, and prognostic assessment of PC.

**INTRODUCTION**

Pancreatic cancer (PC) is associated with poor survival outcome with a 5-year survival of 5%-10%, and a short median survival of 6-8 mo after cancer diagnosis[1]. Most individuals diagnosed with advanced disease are symptomatic whereas early stages of the cancer are generally asymptomatic and often undiagnosed. Hence diagnosis is often made after dissemination. Surgery is the only curative treatment[2]. Regrettably, a large number of patients present with unresectable or metastatic disease at the time of diagnosis. Early detection of PC is essential for treatment with curative intent, typically by surgical resection in combination with neoadjuvant or adjuvant chemotherapy and chemo radiation. The majority of patients can have local recurrence or systematic metastasis even after resection. Screening methods for PC often relies on carbohydrate antigen 19-9 (CA 19-9). CA 19-9 demonstrates relatively low sensitivity and specificity in diagnosing PC[3]. Hence a diagnostic test with high sensitivity and specificity and capable of distinguishing PC at early stages from benign diseases is highly recommended. Table 1 shows common circulating biomarkers for PC[4-19].Comparison of usefulness of various Liquid biopsies used in PC is shown in Table 2[20-30].

**BIOGENESIS OF EXOSOMES**

There is an emerging role of molecular profiling of liquid biopsies for cancer diagnosis and prognostication. Extracellular vesicles (EVs) derived from various body fluids and serum. There are four subclasses of EV based on different sizes like Exosomes (30-150 nm), Oncosomes (100-1000 nm), Ectoderms (100-1000 nm) and Apoptotic bodies (200-2000 nm). Exosome or Exosomes derived proteins, *etc.* are believed to serve as reliable molecular biomarkers. The circulating vesicles in the blood that originate from tumor cells contains immense proteomic and genetic information to monitor cancer progression, metastasis, and drug efficacy[31-33].Exosomes were originally introduced during the culture of sheep reticulocytes *in vitro* by Johnstone *et al*[34]. Exosomes are EVs that are endosomal in origin with a diameter of 40-160 nm (average, 100 nm). The formation of cancer cell derived exosomes is depicted in Figure 1. Initially, exosomes are formed by inward invagination of plasma membrane to form an early endosome. These endosomes form nano-sized vesicles resulting in formation of multi vesicular body (MVB) that contain intraluminal vesicles which contain cytoplasmic components including various nucleic acids and soluble proteins[35]. These intra luminal vesicles are released to the extracellular environment by fusing the MVBs with the plasma membrane. Then with the help of exocytosis, exosomes are released in to circulation.

Exosomes contains many molecules like heat shock proteins, RNAs, DNAs, GTPase, CD63, CD81, CD9, CD82, cholesterol, sphingomyelin, and ceramides. Exosomes facilitate both the transport of essential substances like nucleic acids and proteins into various recipient cells and the communications between cells. The main sources of exosomes are plasma, serum, urine, bile, saliva and breast milk. The secreted exosomes have various cellular functions in cell-to-cell interactions and might be pivotal in the occurrence and development of tumour progression and metastasis[36]. Exosomes have definite role in inflammation, coagulation, and embryo implantation in pregnancy. However, cancer cells are capable of secreting 10 times than normal cells. Hence tumour derived exosomes can provide vast information on cancer. Furthermore, exosomes are potential surrogates of the original cells, hence they are useful for understanding cell biology.

Oncosomes are tumor derived cells and they contain different oncogenic molecules that can modify the cells to encourage cancer growth. Tumor cell-secreted exosomes are responsible for paracrine signalling during tumor progression, tumor-stromal interactions, proliferative pathway activation, and immunosuppression[37]. Tumor derived exosomes enters the cells by a variety of methods, depending on the cells that secrete them and the target cells. Metastatic breast cancer derived exosomes use transcytosis to cross the brain endothelial cells, while the “CDC42-dependent endocytic pathway” was utilized to enter astrocytes during brain metastasis[38].

**EXOSOMES IN INITIATION OF PC AND METASTASIS**

There are increasing evidence that exosomes are involved in the pathogenesis of development of pancreatic inflammation as well as related cancer initiation. Repeated episodes of pancreatitis are a strong risk factor which can eventually increase the risk of PC. The pathogenesis and evolution of many pancreases precancerous conditions, including diabetes mellitus and pancreatitis, have been linked to crucial involvement of exosomes[39]. Exosomes can participate in promoting the transformation of various precancerous like intraductal papillary malignant neoplasm to PDAC. Exosomes are a key factor in initiating angiogenesis, cell migration, and epithelial-mesenchymal transition[40]. Cancer-associated fibroblasts, tumor-associated macrophages and pancreatic stellate cells can promote exosomes, that could promote growth, proliferation, drug resistance, epithelial mesenchymal transition, migration, invasion and metastasis of PC[41]. Interestingly, exosomes initiated from PC cells contains tumor suppressor components which can inhibit the cancer cell proliferation and this could open the pandora box of potential therapeutic value of exosomes[42]. Exosomes promote cancer cell proliferation and initiate metastasis by delivering carcinogenic proteins, cytokines, adhesion molecules and miRNA. Thus, initiate proliferation of tumour by activation of different pathways like phosphoinositide 3-kinase/AKT serine/threonine kinase 1 (Akt) and mitogen-activated protein kinase pathways[43]. The features like weight loss and new-onset diabetes are characteristics of the paraneoplastic effect of PC which mostly precede the diagnosis of the PC. The biological reason of PC-associated diabetes is due to exosomal adrenomedullin, endoplasmic reticulum stress which may result in β-cell dysfunction and diabetes[44]. There is emerging evidence that suggest role of exosome‑mediated immunosuppression in PC. The exosomes have clear role in communications between tumor and immune cells and supposed to have a dynamic role in tumor immunity regulation. Gemcitabine chemotherapy is considered a standard treatment for PC either in combination or monotherapy, based on evidence from many studies which shown a better survival rate and more clinical benefits with median overall survival (OS) of 5 mo to 7 mo[45]. Most of patients with PC ultimately present with rapid disease progression even following chemotherapy with gemcitabine. Tumor derived exosomes can induce the progression of chemotherapy resistance in cancer cells. Chemotherapy agents could also be secreted from the extracellular matrix by exosomes is another reason for chemotherapy resistance. When exposed to gemcitabine, exosomal CAFs which are inherently insensitive to gemcitabine may also leads to chemotherapy resistance. CAF exosome secretion inhibition could decrease proliferation and drug resistance[46].

**ISOLATION OF EXOSOMES**

There are various methods to isolate and characterize exosomes based on their physical and chemical properties. Most popular methods are ultracentrifugation, size exclusion chromatography,magnetic activated cell sorting, membrane filtration and various commercial kits[47]. Western blotting and flow cytometry can be used to analyze and detect exosome markers. Transmission electron microscopy and nanoparticle tracking analysis are other methods to detect exosome.

Liquid biopsy to analyze exosome biomarkers could guide the diagnosis and prognosis of PC. Therefore, the identification of reliable predictive biomarkers for diagnosis and prognosis is an unmet need in PC management. The most common methods for isolation for exosome are summarized in Table 3[48-56] and quantifying methods for exosome are presented in Table 4[48-64]. Methods like Western blotting and enzyme linked immunosorbent assays needs large amounts of sample and extensive technical steps for detection. The comparison of various isolation methods used for exosomes are given in Table 5[65-76].

**EXOSOMES AS DIAGNOSTIC BIOMARKER IN PC**

At present scenario, early diagnosis of PC is very difficult and most are diagnosed at late stage. Mostly CT imaging are used for diagnosis and treatment. CA19-9 which is used in clinical practice has a low specificity and poor ability to distinguish benign pancreatic diseases from PC[77]. Thus, the search for novel early diagnostic markers is a concern for PC diagnosis and treatment. Exosomes are excessively produced in excess by malignant tumours. They also carry information about the tumour genetics and microenvironment, which determines its behaviour and its prognosis[78].Circulating biomarkers are non-invasive and inexpensive for monitoring disease[79].The circulating molecular tumor markers are circulating tumor cells, cell-free DNA, cell-free RNA, circulating tumor proteins, and exosomes. When compared to circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), exosomes are considered as the best diagnostic biomarkers in PC with a sensitivity of 93% and a specificity of 92%[80]. The ctDNA group had similar specificity 0.92 (95%CI 0.88-0.95) but lowest sensitivity. Thus, ctDNA was useful for the diagnosis of PC rather than screening. Whereas CTCs exhibits medium sensitivity and lowest specificity compared to others. The sensitivity, specificity and AUC of ctDNA were 0.6400, 0.9200, and 0.9478 respectively. Glypican 1 (GPC1) is expressed in the serum of patients with PC but not in benign pancreatic disease. Melo *et al*[19] described that Glypican-1 identifies cancer exosomes and could detects early PC. It was described that GPC1+ circulating exosomes could be used as prognostic biomarker in pre- and post-surgical patients. The GPC1+ circulating exosomes could distinguish PC precursor lesions from healthy individuals and benign pancreatic disease. The circulating GPC1+ exosomes levels were higher in PC precursor lesions than the levels in the healthy donor group and benign pancreatic diseases. There is supporting evidence that there is a potential use in early detection of pancreas cancer. Melo *et al*[19] study shows that circulating GPC1+ exosomes exhibit a sensitivity of 100% and specificity of 100%; with a positive predictive value of 100% and a negative predictive value of 100% compared to CA 19-9 which was inferior in distinguishing between pancreas cancer and healthy controls.

The functional role of MicroRNAs has a greater opportunity in developing both prognostic and diagnostic markers. MiRNA -based biomarkers can help in the early diagnosis of disease. A recent study evaluated the expression patterns of miR-21, miR-155, miR-17-5p, and miR-196a in circulating exosomes as biomarkers for PC. The expression profile of miR-17-5p and miR-21 were increased in PC patients, The increased expression of miR-17-5p was seen in unresectable pancreatic patients[81]. miR-155 and miR-21 are over-expressed in PDAC, and can distinguish PC from benign lesions[82]. Upregulated miR-221-3p and miR-212 is associated in PDAC and they are responsible for cancer proliferation in PDAC cells. miR-128 expression is decreased in PC while non-cancerous tissue has a normal level of miR-128. Gemcitabine resistance is associated with downregulation of miRNA200b, miRNA-200c, let-7b, let-7c, let-7d, and let-7e. miR-155 and miR-1246 also have been related to gemcitabine resistance. There are miRNA that function as tumor suppressors in pancreatic ductal cancer like miR-99b, miR-100, miR-99a, miR-34a, miR-148a, miR-200a, miR-200b, and miR-200c. MicroRNAs expression profiles showed that miR-143, miR-29c, miR-148b, miR-150, and miR-96, were present in PDAC and chronic pancreatitis whereas miR-196b, miR-203, miR-196a, miR-210, miR-222, miR-210, miR216, miR-375, and miR-217, were expressed only in pancreatic carcinoma[83]. miR-190, miR-196a, miR-222, miR-15b, miR200b, miR-95, and miR-221 are elevated in pancreatic adenocarcinoma[84]. Nakamura *et al*[85], developed an exosome-based signature for non-invasive and early detection of PDAC. Previous research studies showed that serum Ephrin type-A receptor 2 in exosomes (Exo-EphA2) was expressed highly in PC cells. A study by Wei *et al*[86] the evaluated role of serum Exo-EphA2 as a potential diagnostic biomarker in PC. Serum Exo-EphA2 were higher in PC than in non-cancer pancreatic disease. Exo-EphA2 in combination with CA 19-9 was more useful to discriminate early stage of PC from non-cancer pancreatic disease. Alkaline phosphatase placental-like 2 presents in PC EVs has a potential application in liquid biopsy-based diagnostic tests. Shin *et al*[87] developed ALPPL2 direct and sandwich aptamer-linked immobilized sorbent assay for EVs, which could sensitively and specifically detect membrane protein,17 could be a potential biomarker for early diagnosis of PDAC. Recently, there are reports of exosomal migration inhibitory factor (MIF) may be an attractive sensitive biomarker for PC. MIF is an immunostimulatory cytokine associated with tumorigenesis. Costa-Silva *et al*[88] reported that the pancreatic exosomes are capable of inducing premetastatic niche formation in liver. They demonstrated that the exosome education-induced liver metastasis was abolished by silencing of exosomal MIF. The combined use of exosomal glypican-1 and MIF is a promising tool to identify very early stages of PC. The potential of MIF as a target for the treatment of PDAC should be explored in future.

**EXOSOMES AS PROGNOSTIC BIOMARKER IN PC**

The level of circulating Exo-EphA2 was higher in PC patients when compared to that of healthy controls, suggesting it could be a diagnostic and prognostic marker for PC. In a study by Wei *et al*[86] found that high expression of Exo-EphA2 in PC was associated with shorter OS. Exosomal KRAS mutations seems better than CA 19-9 Levels for the prognostic surveillance in PDAC[17]. A study by Tsuchida *et al*[89] revealed that KRAS mutation detected at baseline with a mutation frequency above 5% indicated poor clinical outcome following monitoring in the treatment course of patients with metastatic PDAC. Costa-Silva *et al*[88] found that MIF was markedly higher in exosomes from stage I PDAC patients who later developed liver metastasis. Thus, it is suggested that higher exosomal MIF may be a prognostic marker for the development of PDAC liver metastasis. Potential role of exosomal biomarkers for prognosis evaluation in PDAC was evaluated in a systematic review and meta-analysis, involving eleven studies comprising 634 patients and seen that detection of positive exosomal biomarkers increased risk of mortality and progression across disease stages. Positive exosomal biomarkers preoperatively had higher risk of mortality in resectable stages than positive exosomal biomarkers in unresectable stages[90].

The better understanding of the prognostic role of miRNAs in PC can be done by profiling miRNAs at different stages of cancer. In a study by Takahasi *et al*[91], authors suggest that plasma exosomal miR-451a may be useful to predict recurrence and prognosis in PDAC patients. The miR-451a had a significant association with tumor, stage and showed the highest upregulation in the stage II patients who showed recurrence after surgery. In a retrospective clinical study by Namkung *et al*[92] comprising 200 pancreatic ductal adenocarcinoma tissue samples, miRNA-574-5p, miRNA-1244, miRNA-145, miRNA-328, miRNA-26b, and miRNA4321 showed association with OS and disease-free survival. Poor survival outcomes have been seen in PDAC with lower expression of *miR-183* and *miR-34a* as well as high expression of *miR-1290*, *miR-155*, *miR-203*, *miR-222*, and *miR-10b*[93]. Similarly, Microarray-based expression profiling of miRNAs derived from exosomes study revealed that miR-451a was the highest upregulated miRNA in stage II patients who developed recurrence after surgery. It was seen that survival rates of the high exosomal miR-451a patients were significantly worse than those of the low miR-451a patients[94].

**TREATMENT MONITORING IN PC**

Currently, one of the most common biomarkers used for so long to monitor the therapeutic responses in PC is CA 19-9. Exosomes have a significant role in monitoring response to therapy and disease progression. Melo *et al*[19] clearly demonstrated that all 190 patients with PDAC serum had higher GPC1+ exosomes than healthy individuals and was an independent prognostic marker for disease specific survival. In view of the fact that CA19-9 is not a reliable marker that correlates with clinical evolution of PC, a combination of CA19-9 together with exosome derived GPC1 could be explored for treatment monitoring and disease progression. Besides early diagnosis and prognosis, clinical utility of exosome proteins is evolving for personalized and posttreatment disease monitoring[95]. Circulating exosomal PD-L1 is an attractive option in disease monitoring. Recently, Chen *et al*[96] study explains the rationale for the application of exosome PD-L1 as a predictor for anti-PD-1 therapy.

**EXOSOMES AS DRUG CARRIERS, THERAPEUTIC TARGETS AND TREATMENT**

Currently, innovators are exploring the utility of exosomes for biomedical applications. Many advanced drug delivery systems that used to deliver various anticancer and antiviral agents explore the use of polymeric nanoparticles and liposomes to encapsulate drug and thus utilize for drug delivery.

Exosomes can be used as therapeutic drugs carriers because of favourable bioavailability, biocompatibility, ability to penetrate biological membranes and immunogenicity[97]. Exosomes can be used as transporters, therapeutic targets and therapeutic drugs.

Due to the favorable bioavailability and biocompatibility with the characteristics of exosomes, there appears a greater future of exosomes used either as parental exosomes or artificially modified exosomes for drug delivery vehicle. To avoid systemic toxicity, drugs can be encapsulated in exosomes and transferred to target cells[98]. Exosomes possess better biocompatibility as drug carriers. It is generally considered that injected exosomes shed from endogenous cells are tolerated with minimal immune reaction. The cargos can be delivered into the tumor microenvironment with the utility of exosomes[99]. Kamerkar *et al*[100] studied modified exosomes for cancer prevention and treatment and revealed that exosomes had a longer retention time in the circulation. Engineered exosomes specialized for malignant KRAS G12D were more successful in targeting oncogenic KRAS. Recent evidence suggests that safety and efficacy of exosomes in treating PC is not far. Exosome-based therapies for cancers have been developed due to the easy permeability of the exosome membrane, low toxic side effects and low immunogenicity. Paclitaxel -loaded exosomes have shown a great potential for delivery of chemotherapy and treatment of drug-resistant cancers[101]. Because of their rapid clearance from blood circulation after systemic administration, targeted delivery of exosomes is highly restricted. The rapid clearance after injection limits their applications for effective and durable therapeutic action. However, recent studies on modification of exosomes for targeted delivery *via* direct modification and genetic engineering to circumvent this limitation is promising. The use of MSCs-derived exosomes loaded with KRAS G12D siRNA to treat metastatic pancreas cancer (NCT03608631) is promising[102]. Mittal *et al*[103] also showed the efficacy of administration of micelles of gemcitabine and the tumor suppressor *miRNA-205* for the treatment of pancreas. Masamune *et al*[104] found that hypoxic environment in PC can release several angiogenic factors that may induce proliferation and angiogenesis. Understanding of these interactions under hypoxia is critical for angiogenic regulation in PDAC, which will also help to develop new anti-angiogenesis therapeutic strategies[105].

**CONCLUSION**

Even though there are several limitations in implementing exosome analysis clinically, it is a promising diagnostic and therapeutic tool for PC. The role of exosomes in cancer treatment continues to evolve.

**ACKNOWLEDGEMENTS**

I would like to convey my gratitude to Malavika Anoop, Standard X of ST Thomas Central School, Mukkolakkal, Thiruvananthapuram, Kerala for her invaluable assistance in completing my digital art work for this article.

**REFERENCES**

1 **Rawla P**, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World J Oncol* 2019; **10**: 10-27 [PMID: 30834048 DOI: 10.14740/wjon1166]

2 **Barros AG**, Pulido CF, Machado M, Brito MJ, Couto N, Sousa O, Melo SA, Mansinho H. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). *Int J Oncol* 2021; **59** [PMID: 34859257 DOI: 10.3892/ijo.2021.5290]

3 **Poruk KE**, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. *Curr Mol Med* 2013; **13**: 340-351 [PMID: 23331006 DOI: 10.2174/1566524011313030003]

4 **Ballehaninna UK**, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. *J Gastrointest Oncol* 2012; **3**: 105-119 [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021]

5 **Kriz D**, Ansari D, Andersson R. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma. *Clin Transl Oncol* 2020; **22**: 2170-2174 [PMID: 32447642 DOI: 10.1007/s12094-020-02372-0]

6 **Zhang X**, Shi S, Zhang B, Ni Q, Yu X, Xu J. Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. *Am J Cancer Res* 2018; **8**: 332-353 [PMID: 29636993]

7 **Brand RE**, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE. Serum biomarker panels for the detection of pancreatic cancer. *Clin Cancer Res* 2011; **17**: 805-816 [PMID: 21325298 DOI: 10.1158/1078-0432.CCR-10-0248]

8 **Liu L**, Xu HX, Wang WQ, Wu CT, Xiang JF, Liu C, Long J, Xu J, Fu de L, Ni QX, Houchen CW, Postier RG, Li M, Yu XJ. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. *Oncotarget* 2016; **7**: 5943-5956 [PMID: 26745601 DOI: 10.18632/oncotarget.6819]

9 **Gold DV**, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. *J Clin Oncol* 2006; **24**: 252-258 [PMID: 16344318 DOI: 10.1200/jco.2005.02.8282]

10 **Martini V**, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, Kulemann B. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. *Cancers (Basel)* 2019; **11** [PMID: 31717773 DOI: 10.3390/cancers11111659]

11 **Tjensvoll K**, Nordgård O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. *Int J Cancer* 2014; **134**: 1-8 [PMID: 23447365 DOI: 10.1002/ijc.28134]

12 **Ankeny JS**, Court CM, Hou S, Li Q, Song M, Wu D, Chen JF, Lee T, Lin M, Sho S, Rochefort MM, Girgis MD, Yao J, Wainberg ZA, Muthusamy VR, Watson RR, Donahue TR, Hines OJ, Reber HA, Graeber TG, Tseng HR, Tomlinson JS. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. *Br J Cancer* 2016; **114**: 1367-1375 [PMID: 27300108 DOI: 10.1038/bjc.2016.121]

13 **Okada T**, Mizukami Y, Ono Y, Sato H, Hayashi A, Kawabata H, Koizumi K, Masuda S, Teshima S, Takahashi K, Katanuma A, Omori Y, Iwano H, Yamada M, Yokochi T, Asahara S, Kawakubo K, Kuwatani M, Sakamoto N, Enomoto K, Goto T, Sasajima J, Fujiya M, Ueda J, Matsumoto S, Taniue K, Sugitani A, Karasaki H, Okumura T. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance. *J Gastroenterol* 2020; **55**: 1183-1193 [PMID: 32939577 DOI: 10.1007/s00535-020-01724-5]

14 **Takai E**, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N, Suzuki M, Furukawa E, Kato M, Hayashi H, Kohno T, Ueno H, Shimada K, Okusaka T, Nakagama H, Shibata T, Yachida S. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. *Sci Rep* 2015; **5**: 18425 [PMID: 26669280 DOI: 10.1038/srep18425]

15 **Liu JH**, Chen G, Dang YW, Li CJ, Luo DZ. Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues. *Asian Pac J Cancer Prev* 2014; **15**: 2971-2977 [PMID: 24815433 DOI: 10.7314/apjcp.2014.15.7.2971]

16 **Schwarzenbach H**, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. *Nat Rev Clin Oncol* 2014; **11**: 145-156 [PMID: 24492836 DOI: 10.1038/nrclinonc.2014.5]

17 **Allenson K**, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. *Ann Oncol* 2017; **28**: 741-747 [PMID: 28104621 DOI: 10.1093/annonc/mdx004]

18 **Lorenzon L**, Blandino G. Glypican-1 exosomes: do they initiate a new era for early pancreatic cancer diagnosis? *Transl Gastroenterol Hepatol* 2016; **1**: 8 [PMID: 28164166 DOI: 10.21037/tgh.2016.01.07]

19 **Melo SA**, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* 2015; **523**: 177-182 [PMID: 26106858 DOI: 10.1038/nature14581]

20 **Raufi AG**, May MS, Hadfield MJ, Seyhan AA, El-Deiry WS. Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer. *Int J Mol Sci* 2023; **24** [PMID: 36835649 DOI: 10.3390/ijms24044238]

21 **Yadav DK**, Bai X, Yadav RK, Singh A, Li G, Ma T, Chen W, Liang T. Liquid biopsy in pancreatic cancer: the beginning of a new era. *Oncotarget* 2018; **9**: 26900-26933 [PMID: 29928492 DOI: 10.18632/oncotarget.24809]

22 **Han L**, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. *Tumour Biol* 2014; **35**: 2473-2480 [PMID: 24218336 DOI: 10.1007/s13277-013-1327-5]

23 **Ma M**, Zhu H, Zhang C, Sun X, Gao X, Chen G. "Liquid biopsy"-ctDNA detection with great potential and challenges. *Ann Transl Med* 2015; **3**: 235 [PMID: 26539452 DOI: 10.3978/j.issn.2305-5839.2015.09.29]

24 **Yi X**, Ma J, Guan Y, Chen R, Yang L, Xia X. The feasibility of using mutation detection in ctDNA to assess tumor dynamics. *Int J Cancer* 2017; **140**: 2642-2647 [PMID: 28124376 DOI: 10.1002/ijc.30620]

25 **Mikamori M**, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, Asaoka T, Noda T, Wada H, Kawamoto K, Gotoh K, Takeda Y, Tanemura M, Mori M, Doki Y. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. *Sci Rep* 2017; **7**: 42339 [PMID: 28198398 DOI: 10.1038/srep42339]

26 **Ohuchida K**, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, Ueda J, Nagai E, Hashizume M, Tanaka M. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. *Ann Surg Oncol* 2011; **18**: 2381-2387 [PMID: 21347785 DOI: 10.1245/s10434-011-1602-x]

27 **van den Boorn JG**, Dassler J, Coch C, Schlee M, Hartmann G. Exosomes as nucleic acid nanocarriers. *Adv Drug Deliv Rev* 2013; **65**: 331-335 [PMID: 22750807 DOI: 10.1016/j.addr.2012.06.011]

28 **Heredia-Soto V**, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? *Cancers (Basel)* 2021; **13** [PMID: 33924143 DOI: 10.3390/cancers13081986]

29 **Arneth B**. Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. *BMC Cancer* 2018; **18**: 527 [PMID: 29728089 DOI: 10.1186/s12885-018-4433-3]

30 **Makler A**, Asghar W. Exosomal biomarkers for cancer diagnosis and patient monitoring. *Expert Rev Mol Diagn* 2020; **20**: 387-400 [PMID: 32067543 DOI: 10.1080/14737159.2020.1731308]

31 **Li P**, Kaslan M, Lee SH, Yao J, Gao Z. Progress in Exosome Isolation Techniques. *Theranostics* 2017; **7**: 789-804 [PMID: 28255367 DOI: 10.7150/thno.18133]

32 **Paolini L**, Zendrini A, Di Noto G, Busatto S, Lottini E, Radeghieri A, Dossi A, Caneschi A, Ricotta D, Bergese P. Residual matrix from different separation techniques impacts exosome biological activity. *Sci Rep* 2016; **6**: 23550 [PMID: 27009329 DOI: 10.1038/srep23550]

33 **Dreyer F**, Baur A. Biogenesis and Functions of Exosomes and Extracellular Vesicles. *Methods Mol Biol* 2016; **1448**: 201-216 [PMID: 27317183 DOI: 10.1007/978-1-4939-3753-0\_15]

34 **Johnstone RM**, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem* 1987; **262**: 9412-9420 [PMID: 3597417 DOI: 10.1016/S0021-9258(18)48095-7]

35 **Kowal J**, Tkach M, Théry C. Biogenesis and secretion of exosomes. *Curr Opin Cell Biol* 2014; **29**: 116-125 [PMID: 24959705 DOI: 10.1016/j.ceb.2014.05.004]

36 **Nuzhat Z**, Kinhal V, Sharma S, Rice GE, Joshi V, Salomon C. Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression. *Oncotarget* 2017; **8**: 17279-17291 [PMID: 27999198 DOI: 10.18632/oncotarget.13973]

37 **Patel G**, Agnihotri TG, Gitte M, Shinde T, Gomte SS, Goswami R, Jain A. Exosomes: a potential diagnostic and treatment modality in the quest for counteracting cancer. *Cell Oncol (Dordr)* 2023: 1-21 [PMID: 37040056 DOI: 10.1007/s13402-023-00810-z]

38 **Chen H**, Chengalvala V, Hu H, Sun D. Tumor-derived exosomes: Nanovesicles made by cancer cells to promote cancer metastasis. *Acta Pharm Sin B* 2021; **11**: 2136-2149 [PMID: 34522581 DOI: 10.1016/j.apsb.2021.04.012]

39 **Ruze R**, Song J, Yin X, Chen Y, Xu R, Wang C, Zhao Y. Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review. *Signal Transduct Target Ther* 2023; **8**: 139 [PMID: 36964133 DOI: 10.1038/s41392-023-01376-w]

40 **Sun W**, Ren Y, Lu Z, Zhao X. The potential roles of exosomes in pancreatic cancer initiation and metastasis. *Mol Cancer* 2020; **19**: 135 [PMID: 32878635 DOI: 10.1186/s12943-020-01255-w]

41 **Zhang YF**, Zhou YZ, Zhang B, Huang SF, Li PP, He XM, Cao GD, Kang MX, Dong X, Wu YL. Pancreatic cancer-derived exosomes promoted pancreatic stellate cells recruitment by pancreatic cancer. *J Cancer* 2019; **10**: 4397-4407 [PMID: 31413760 DOI: 10.7150/jca.27590]

42 **Beloribi S**, Ristorcelli E, Breuzard G, Silvy F, Bertrand-Michel J, Beraud E, Verine A, Lombardo D. Exosomal lipids impact notch signaling and induce death of human pancreatic tumoral SOJ-6 cells. *PLoS One* 2012; **7**: e47480 [PMID: 23094054 DOI: 10.1371/journal.pone.0047480]

43 **Liu H**, Qiao S, Fan X, Gu Y, Zhang Y, Huang S. Role of exosomes in pancreatic cancer. *Oncol Lett* 2021; **21**: 298 [PMID: 33732374 DOI: 10.3892/ol.2021.12559]

44 **Sagar G**, Sah RP, Javeed N, Dutta SK, Smyrk TC, Lau JS, Giorgadze N, Tchkonia T, Kirkland JL, Chari ST, Mukhopadhyay D. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. *Gut* 2016; **65**: 1165-1174 [PMID: 26061593 DOI: 10.1136/gutjnl-2014-308350]

45 **Ouyang G**, Wu Y, Liu Z, Lu W, Li S, Hao S, Pan G. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2021; **100**: e27870 [PMID: 35049189 DOI: 10.1097/MD.0000000000027870]

46 **Richards KE**, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. *Oncogene* 2017; **36**: 1770-1778 [PMID: 27669441 DOI: 10.1038/onc.2016.353]

47 **Lan B**, Zeng S, Grützmann R, Pilarsky C. The Role of Exosomes in Pancreatic Cancer. *Int J Mol Sci* 2019; **20** [PMID: 31487880 DOI: 10.3390/ijms20184332]

48 **Ko J**, Carpenter E, Issadore D. Detection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices. *Analyst* 2016; **141**: 450-460 [PMID: 26378496 DOI: 10.1039/c5an01610j]

49 **Bobrie A**, Colombo M, Krumeich S, Raposo G, Théry C. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. *J Extracell Vesicles* 2012; **1** [PMID: 24009879 DOI: 10.3402/jev.v1i0.18397]

50 **Zhang Z**, Wang C, Li T, Liu Z, Li L. Comparison of ultracentrifugation and density gradient separation methods for isolating Tca8113 human tongue cancer cell line-derived exosomes. *Oncol Lett* 2014; **8**: 1701-1706 [PMID: 25202395 DOI: 10.3892/ol.2014.2373]

51 **Wang Z**, Wu HJ, Fine D, Schmulen J, Hu Y, Godin B, Zhang JX, Liu X. Ciliated micropillars for the microfluidic-based isolation of nanoscale lipid vesicles. *Lab Chip* 2013; **13**: 2879-2882 [PMID: 23743667 DOI: 10.1039/c3lc41343h]

52 **Lee K**, Shao H, Weissleder R, Lee H. Acoustic purification of extracellular microvesicles. *ACS Nano* 2015; **9**: 2321-2327 [PMID: 25672598 DOI: 10.1021/nn506538f]

53 **Dudani JS**, Gossett DR, Tse HT, Lamm RJ, Kulkarni RP, Carlo DD. Rapid inertial solution exchange for enrichment and flow cytometric detection of microvesicles. *Biomicrofluidics* 2015; **9**: 014112 [PMID: 25713694 DOI: 10.1063/1.4907807]

54 **Raposo G**, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. *J Cell Biol* 2013; **200**: 373-383 [PMID: 23420871 DOI: 10.1083/jcb.201211138]

55 **Mathivanan S**, Lim JW, Tauro BJ, Ji H, Moritz RL, Simpson RJ. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. *Mol Cell Proteomics* 2010; **9**: 197-208 [PMID: 19837982 DOI: 10.1074/mcp.M900152-MCP200]

56 **Vaidyanathan R**, Naghibosadat M, Rauf S, Korbie D, Carrascosa LG, Shiddiky MJ, Trau M. Detecting exosomes specifically: a multiplexed device based on alternating current electrohydrodynamic induced nanoshearing. *Anal Chem* 2014; **86**: 11125-11132 [PMID: 25324037 DOI: 10.1021/ac502082b]

57 **Berne BJ**, Pecora R. Dynamic light scattering with applications to chemistry, biology, and physics, Courier Corporation. United Kingdom: Dover Publications, 2000 [DOI: 10.1021/ed054pa430.1]

58 **Lyons AB**, Parish CR. Determination of lymphocyte division by flow cytometry. *J Immunol Methods* 1994; **171**: 131-137 [PMID: 8176234 DOI: 10.1016/0022-1759(94)90236-4]

59 **van der Pol E**, Hoekstra AG, Sturk A, Otto C, van Leeuwen TG, Nieuwland R. Optical and non-optical methods for detection and characterization of microparticles and exosomes. *J Thromb Haemost* 2010; **8**: 2596-2607 [PMID: 20880256 DOI: 10.1111/j.1538-7836.2010.04074.x]

60 **McLeod E**, Dincer TU, Veli M, Ertas YN, Nguyen C, Luo W, Greenbaum A, Feizi A, Ozcan A. High-throughput and label-free single nanoparticle sizing based on time-resolved on-chip microscopy. *ACS Nano* 2015; **9**: 3265-3273 [PMID: 25688665 DOI: 10.1021/acsnano.5b00388]

61 **Platt M**, Willmott GR, Lee GU. Resistive pulse sensing of analyte-induced multicomponent rod aggregation using tunable pores. *Small* 2012; **8**: 2436-2444 [PMID: 22570187 DOI: 10.1002/smll.201200058]

62 **Shao H**, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, Lee H. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. *Nat Med* 2012; **18**: 1835-1840 [PMID: 23142818 DOI: 10.1038/nm.2994]

63 **Zhu L**, Wang K, Cui J, Liu H, Bu X, Ma H, Wang W, Gong H, Lausted C, Hood L, Yang G, Hu Z. Label-free quantitative detection of tumor-derived exosomes through surface plasmon resonance imaging. *Anal Chem* 2014; **86**: 8857-8864 [PMID: 25090139 DOI: 10.1021/ac5023056]

64 **Elshafey R**, Tavares AC, Siaj M, Zourob M. Electrochemical impedance immunosensor based on gold nanoparticles-protein G for the detection of cancer marker epidermal growth factor receptor in human plasma and brain tissue. *Biosens Bioelectron* 2013; **50**: 143-149 [PMID: 23850780 DOI: 10.1016/j.bios.2013.05.063]

65 **Correll VL**, Otto JJ, Risi CM, Main BP, Boutros PC, Kislinger T, Galkin VE, Nyalwidhe JO, Semmes OJ, Yang L. Optimization of small extracellular vesicle isolation from expressed prostatic secretions in urine for in-depth proteomic analysis. *J Extracell Vesicles* 2022; **11**: e12184 [PMID: 35119778 DOI: 10.1002/jev2.12184]

66 **Witwer KW**, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, Nolte-'t Hoen EN, Piper MG, Sivaraman S, Skog J, Théry C, Wauben MH, Hochberg F. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. *J Extracell Vesicles* 2013; **2** [PMID: 24009894 DOI: 10.3402/jev.v2i0.20360]

67 **Kim K**, Son T, Hong JS, Kwak TJ, Jeong MH, Weissleder R, Im H. Physisorption of Affinity Ligands Facilitates Extracellular Vesicle Detection with Low Non-Specific Binding to Plasmonic Gold Substrates. *ACS Appl Mater Interfaces* 2022 [PMID: 35653580 DOI: 10.1021/acsami.2c07317]

68 **Kamei N**, Nishimura H, Matsumoto A, Asano R, Muranaka K, Fujita M, Takeda M, Hashimoto H, Takeda-Morishita M. Comparative study of commercial protocols for high recovery of high-purity mesenchymal stem cell-derived extracellular vesicle isolation and their efficient labeling with fluorescent dyes. *Nanomedicine* 2021; **35**: 102396 [PMID: 33864911 DOI: 10.1016/j.nano.2021.102396]

69 **Guo J**, Wu C, Lin X, Zhou J, Zhang J, Zheng W, Wang T, Cui Y. Establishment of a simplified dichotomic size-exclusion chromatography for isolating extracellular vesicles toward clinical applications. *J Extracell Vesicles* 2021; **10**: e12145 [PMID: 34514732 DOI: 10.1002/jev2.12145]

70 **Sidhom K**, Obi PO, Saleem A. A Review of Exosomal Isolation Methods: Is Size Exclusion Chromatography the Best Option? *Int J Mol Sci* 2020; **21** [PMID: 32899828 DOI: 10.3390/ijms21186466]

71 **Hu GW**, Li Q, Niu X, Hu B, Liu J, Shen XL, Wang Y, Deng ZF. Stirring ultrafiltration: a new method to isolate exosome. *Dier Junyi Daxue Xuebao* 2014; **35**: 598-602 [DOI: 10.3724/SP.J.1008.2014.00598]

72 **Gao J**, Li A, Hu J, Feng L, Liu L, Shen Z. Recent developments in isolating methods for exosomes. *Front Bioeng Biotechnol* 2022; **10**: 1100892 [PMID: 36714629 DOI: 10.3389/fbioe.2022.1100892]

73 **Liu F**, Vermesh O, Mani V, Ge TJ, Madsen SJ, Sabour A, Hsu EC, Gowrishankar G, Kanada M, Jokerst JV, Sierra RG, Chang E, Lau K, Sridhar K, Bermudez A, Pitteri SJ, Stoyanova T, Sinclair R, Nair VS, Gambhir SS, Demirci U. The Exosome Total Isolation Chip. *ACS Nano* 2017; **11**: 10712-10723 [PMID: 29090896 DOI: 10.1021/acsnano.7b04878]

74 **Zhu L**, Sun HT, Wang S, Huang SL, Zheng Y, Wang CQ, Hu BY, Qin W, Zou TT, Fu Y, Shen XT, Zhu WW, Geng Y, Lu L, Jia HL, Qin LX, Dong QZ. Isolation and characterization of exosomes for cancer research. *J Hematol Oncol* 2020; **13**: 152 [PMID: 33168028 DOI: 10.1186/s13045-020-00987-y]

75 **Chen Z**, Cheng SB, Cao P, Qiu QF, Chen Y, Xie M, Xu Y, Huang WH. Detection of exosomes by ZnO nanowires coated three-dimensional scaffold chip device. *Biosens Bioelectron* 2018; **122**: 211-216 [PMID: 30265971 DOI: 10.1016/j.bios.2018.09.033]

76 **Yu LL**, Zhu J, Liu JX, Jiang F, Ni WK, Qu LS, Ni RZ, Lu CH, Xiao MB. A Comparison of Traditional and Novel Methods for the Separation of Exosomes from Human Samples. *Biomed Res Int* 2018; **2018**: 3634563 [PMID: 30148165 DOI: 10.1155/2018/3634563]

77 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

78 **Chen K**, Wang Q, Kornmann M, Tian X, Yang Y. The Role of Exosomes in Pancreatic Cancer From Bench to Clinical Application: An Updated Review. *Front Oncol* 2021; **11**: 644358 [PMID: 33718244 DOI: 10.3389/fonc.2021.644358]

79 **Pantel K**, Speicher MR. The biology of circulating tumor cells. *Oncogene* 2016; **35**: 1216-1224 [PMID: 26050619 DOI: 10.1038/onc.2015.192]

80 **Zhu Y**, Zhang H, Chen N, Hao J, Jin H, Ma X. Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis. *Medicine (Baltimore)* 2020; **99**: e18581 [PMID: 32011436 DOI: 10.1097/MD.0000000000018581]

81 **Que R**, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. *World J Surg Oncol* 2013; **11**: 219 [PMID: 24007214 DOI: 10.1186/1477-7819-11-219]

82 **Kabiraj L**, Kundu A. Potential role of microRNAs in pancreatic cancer manifestation: a review. *J Egypt Natl Canc Inst* 2022; **34**: 26 [PMID: 35718815 DOI: 10.1186/s43046-022-00127-2]

83 **Frampton AE**, Krell J, Prado MM, Gall TM, Abbassi-Ghadi N, Del Vecchio Blanco G, Funel N, Giovannetti E, Castellano L, Basyouny M, Habib NA, Kaltsidis H, Vlavianos P, Stebbing J, Jiao LR. Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. *Oncotarget* 2016; **7**: 28556-28569 [PMID: 27086919 DOI: 10.18632/oncotarget.8699]

84 **Reese M**, Flammang I, Yang Z, Dhayat SA. Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma. *Cancers (Basel)* 2020; **12** [PMID: 31941049 DOI: 10.3390/cancers12010197]

85 **Nakamura K**, Zhu Z, Roy S, Jun E, Han H, Munoz RM, Nishiwada S, Sharma G, Cridebring D, Zenhausern F, Kim S, Roe DJ, Darabi S, Han IW, Evans DB, Yamada S, Demeure MJ, Becerra C, Celinski SA, Borazanci E, Tsai S, Kodera Y, Park JO, Bolton JS, Wang X, Kim SC, Von Hoff D, Goel A. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. *Gastroenterology* 2022; **163**: 1252-1266.e2 [PMID: 35850192 DOI: 10.1053/j.gastro.2022.06.090]

86 **Wei Q**, Li Z, Feng H, Ren L. Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer. *Cancer Manag Res* 2021; **13**: 3675-3683 [PMID: 33994808 DOI: 10.2147/CMAR.S304719]

87 **Shin HS**, Jung SB, Park S, Dua P, Lee DK. ALPPL2 Is a Potential Diagnostic Biomarker for Pancreatic Cancer-Derived Extracellular Vesicles. *Mol Ther Methods Clin Dev* 2019; **15**: 204-210 [PMID: 31687420 DOI: 10.1016/j.omtm.2019.08.016]

88 **Costa-Silva B**, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. *Nat Cell Biol* 2015; **17**: 816-826 [PMID: 25985394 DOI: 10.1038/ncb3169]

89 **Tsuchida K**. Evaluation of clinical outcomes of pancreatic cancer patients using circulating nucleic acids. *Transl Gastroenterol Hepatol* 2019; **4**: 2 [PMID: 30854489 DOI: 10.21037/tgh.2018.12.09]

90 **Bunduc S**, Gede N, Váncsa S, Lillik V, Kiss S, Juhász MF, Erőss B, Szakács Z, Gheorghe C, Mikó A, Hegyi P. Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma-a systematic review and meta-analysis. *Transl Res* 2022; **244**: 126-136 [PMID: 35066189 DOI: 10.1016/j.trsl.2022.01.001]

91 **Takahasi K**, Iinuma H, Wada K, Minezaki S, Kawamura S, Kainuma M, Ikeda Y, Shibuya M, Miura F, Sano K. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. *J Hepatobiliary Pancreat Sci* 2018; **25**: 155-161 [PMID: 29130611 DOI: 10.1002/jhbp.524]

92 **Namkung J**, Kwon W, Choi Y, Yi SG, Han S, Kang MJ, Kim SW, Park T, Jang JY. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value. *J Gastroenterol Hepatol* 2016; **31**: 1160-1167 [PMID: 26644397 DOI: 10.1111/jgh.13253]

93 **Li A**, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. *Clin Cancer Res* 2013; **19**: 3600-3610 [PMID: 23697990 DOI: 10.1158/1078-0432.CCR-12-3092]

94 **Bandres E**, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J, Garcia-Foncillas J. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. *Clin Cancer Res* 2009; **15**: 2281-2290 [PMID: 19318487 DOI: 10.1158/1078-0432.CCR-08-1818]

95 **Jafari A**, Babajani A, Abdollahpour-Alitappeh M, Ahmadi N, Rezaei-Tavirani M. Exosomes and cancer: from molecular mechanisms to clinical applications. *Med Oncol* 2021; **38**: 45 [PMID: 33743101 DOI: 10.1007/s12032-021-01491-0]

96 **Chen G**, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature* 2018; **560**: 382-386 [PMID: 30089911 DOI: 10.1038/s41586-018-0392-8]

97 **Song H**, Liu B, Dong B, Xu J, Zhou H, Na S, Liu Y, Pan Y, Chen F, Li L, Wang J. Exosome-Based Delivery of Natural Products in Cancer Therapy. *Front Cell Dev Biol* 2021; **9**: 650426 [PMID: 33738290 DOI: 10.3389/fcell.2021.650426]

98 **Rajput A**, Varshney A, Bajaj R, Pokharkar V. Exosomes as New Generation Vehicles for Drug Delivery: Biomedical Applications and Future Perspectives. *Molecules* 2022; **27** [PMID: 36364116 DOI: 10.3390/molecules27217289]

99 **Butreddy A**, Kommineni N, Dudhipala N. Exosomes as Naturally Occurring Vehicles for Delivery of Biopharmaceuticals: Insights from Drug Delivery to Clinical Perspectives. *Nanomaterials (Basel)* 2021; **11** [PMID: 34204903 DOI: 10.3390/nano11061481]

100 **Kamerkar S**, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. *Nature* 2017; **546**: 498-503 [PMID: 28607485 DOI: 10.1038/nature22341]

101 **Pascucci L**, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Viganò L, Locatelli A, Sisto F, Doglia SM, Parati E, Bernardo ME, Muraca M, Alessandri G, Bondiolotti G, Pessina A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. *J Control Release* 2014; **192**: 262-270 [PMID: 25084218 DOI: 10.1016/j.jconrel.2014.07.042]

102 **Chen H**, Wang L, Zeng X, Schwarz H, Nanda HS, Peng X, Zhou Y. Exosomes, a New Star for Targeted Delivery. *Front Cell Dev Biol* 2021; **9**: 751079 [PMID: 34692704 DOI: 10.3389/fcell.2021.751079]

103 **Mittal A**, Chitkara D, Behrman SW, Mahato RI. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. *Biomaterials* 2014; **35**: 7077-7087 [PMID: 24836307 DOI: 10.1016/j.biomaterials.2014.04.053]

104 **Masamune A**, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. *Am J Physiol Gastrointest Liver Physiol* 2008; **295**: G709-G717 [PMID: 18669622 DOI: 10.1152/ajpgi.90356.2008]

105 **Tao J**, Yang G, Zhou W, Qiu J, Chen G, Luo W, Zhao F, You L, Zheng L, Zhang T, Zhao Y. Targeting hypoxic tumor microenvironment in pancreatic cancer. *J Hematol Oncol* 2021; **14**: 14 [PMID: 33436044 DOI: 10.1186/s13045-020-01030-w]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 22, 2023

**First decision:** April 17, 2023

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Feliu J, Spain; Gao W, China; Zhao CF, China **S-Editor:** Chen YL **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 Diagrammatic representation of formation of cancer cell derived exosomes.** MVB: Multi vesicular body.

**Table 1 Circulating biomarkers in pancreatic cancer**

|  |  |  |
| --- | --- | --- |
| **Biomarker** | **Type** | **Role in pancreatic cancer** |
| CA19-9 | Protein | Widely used biomarkers to aid in the diagnosis[4] |
| Poor screening tool in asymptomatic patients |
| Elevated in many benign gastrointestinal conditions as well as other malignancies, including pancreatitis, cirrhosis, cholangitis, and colorectal cancer[5] |
| 5%-10% of the Caucasian population possesses a Lewis a-/b- genotype and thus does not express CA19-9 |
| CEA | Glycoprotein | Elevated across several cancers[6] |
| Non specific |
| Inferior sensitivity of CEA compared to ca19-9[7] |
| CA125 | Glycoprotein | Associated with ovarian cancer, CRC and cholangiocarcinoma[8] |
| Superiority to CA19-9 in predicting resectability of PC, along with correlating with metastasis-associated disease burden |
| Anti-MUC1 antibody | Antibody | Anti-MUC1 antibody assays showed a sensitivity and specificity of 77% and 95%, respectively, in discriminating pancreatic cancer from pancreatitis[9] |
| CTCs | Tumour cells | CTCs had moderate diagnostic value in PC[10] |
| Several studies have demonstrated isolation of CTCs regardless of stage among localized, locally advanced, or metastatic patients |
| Conflicting evidence on CTC positivity is correlated with survivability |
| In ombination with CA19-9, it was reported to have a superior sensitivity and specificity of 97.8% and 83.3% respectively, compared to when used in isolation[11] |
| The presence of CTCs in 54/72 patients with confirmed PDAC (sensitivity = 75.0%, specificity = 96.4%, AUROC = 0.867, 95%CI = 0.798-0.935, and *P* < 0.001)[12] |
| A cut-off of ≥ 3 CTCs in 4 mL blood could differentiate between local/regional and metastatic disease (AUROC = 0.885; 95%CI = 0.800-0.969; and *P* < 0.001) |
| cfDNA | DNA | Plasma ctDNA quantification of hot-spot mutations in KRAS and GNAS are useful in predicting tumor burden in patients diagnosed with PC[13] |
| Digital PCR provided accurate tumor-derived mutant KRAS detection in plasma in resectable PC and improved post-resection recurrence prediction compared to CA19-9[14] |
| Detection of plasma cfDNA mutations and copy number alterations may be helpful in pancreatic cancer prognosis and diagnosis |
| Its sensitivity and specificity in identification of clinically relevant KRAS mutations was 87% and 99% respectively[15] |
| Cell-free RNA | RNA | Higher expression of lncRNA MALAT1 has been shown to correlate with poorer PDAC survival[16] |
| Several microRNAs have also been associated with PDAC (*i.e.*, miR-21 and miR-155), and correlate with tumor stage or prognosis[17] |
| EVs | Exosomes | KRAS G12D mutations were identified in 7.4% of control patients, 67% of localized PDAC, 80% of locally advanced PDAC, and 85% of metastatic PDAC patients[18] |
| GPC1 EVs could be detected in both pancreatic precursor lesions and pancreatic cancer, and could distinguish between any evidence of malignancy and healthy patients with an AUC of 1 (100% sensitivity, 100% specificity)[19] |
| miRNA isolated from EVs revealed a cocktail of miRNAs (miR-1246, 4644, 3976, 4306) upregulated in 83% of pancreatic cancer derived EV |
| Glypican-1 exosomes are a potential biomarker for PC |

CA: Carbohydrate antigen; PDAC: Pancreatic ductal adenocarcinoma; PC: Pancreatic cancer; CEA: Carcinoembryonic antigen; CTCs: Circulating tumour cells; cfDNA: Cell-free DNA; EVs: Extracellular vesicles; AUROC: Area under the curve.

**Table 2 Comparison of usefulness of various liquid biopsies in pancreatic cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Item** | **CTC**[20-22] | **Ct DNA**[21,23,24] | **Exosomes**[20,25-28] | **CA 19-9**[20,21,28-30] |
| Origin | Viable tumor cells | cfDNA, viable tumor cells, CTCs | DNA, proteins, lipids, RNAs metabolites, and tumor cells | Ductal cells in the pancreas, biliary system, and epithelial cells in the stomach, colon, uterus, and salivary glands |
| Samples used | Plasma | Frozen plasma, urine and other biofluids | Frozen plasma, urine and other biofluids | Plasma |
| Methods | CellSearch, MACS, Dynabeads, microfluidic, SE-iFISH, CD45/CEP8/DAPI staining-FISH, anti-EpCAM Portal-vein blood | Real-time quantitative PCR, digital PCR, droplet digital PCR, next-generation sequencing; commercial liquid biopsy platforms: GuardantTM (breast, colon, and lung cancers and multi-cancer detection) FoundationOne® (multi-cancer detection); signateraTM (colorectal cancer), Galleri (multi-cancer detection), CancerSEEK (multi-cancer detection), TempusTM (multi-cancer detection), Caris (bioinformatics testing of both circulating DNA and RNA) | Ultracentrifugation, ExoChip, precipitation, size-based isolation immunoaffinity-based isolation microfluidics-based isolation | Radio immuno assay |
| Mutation analysis | Yes | Yes | Yes | No |
| Drug delivery vehicle | No | No | Yes | No |
| Sensitivity | 76.0% | 65.0% | 50.0%-85.0% | 78.2% |
| Specificity | 68.0% | 75.0% | 90.0% | 82.8% |
| Usage in clinics | Diagnosis of PDAC, prognosis/prediction of PDAC | Diagnosis of PDAC; monitoring Treatment efficacy; monitoring of disease progression | Diagnosis and prognosis of PDAC; prognosis/prediction of PDAC | Combining ct DNA with CA 19-9 levels could improve diagnostic sensitivity to 98%, and specificity to 97%; monitoring treatment efficacy; monitoring of disease progression |

PDAC: Pancreatic ductal adenocarcinoma; CTC: Circulating tumour cells; CA: Carbohydrate antigen; ctDNA: Circulating tumor DNA.

**Table 3 Different isolation methods for exosome**

|  |  |  |  |
| --- | --- | --- | --- |
| **Method** | **Sample volume** | **Time** | **Ref.** |
| Ultracentrifugation | Low | Approximately 5 h | [48,49] |
| Density-gradient | Low | Approximately 5 h | [50] |
| Nanopillar | 30 μL | Approximately 10 min | [51] |
| Acoustic-based | 0.4-0.7 μL/min | < 30 min | [52] |
| Inertial lift force-based | 70 μL/min | > 4 h | [53] |
| Surface-modified | 4-16 μL/min | < 1 h | [53-55] |
| Nanoshearing | Not mentioned | < 3 h | [56] |

**Table 4 Different** **quantifying methods for exosome**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Method** | **Size range** | **Specificity** | **Time** | **Ref.** |
| Nanoparticle tracking analysis | 10 nm-2 μm | Immunoaffinity | < 1 h | [48] |
| Dynamic light scattering | 10 nm-8 μm | Size | < 1 h | [57] |
| Electron microscopy | 10 nm | Size | < 1 h | [58,59] |
| Nanopore | > 10 nm | Size | < 1 h | [60,61] |
| Magnetic resonance | Wide range | Immunoaffinity | < 10 min | [62] |
| Electrochemical and plasmonic | Depends on binding | Immunoaffinity | < 10 min | [63,64] |

**Table 5 Comparison of various isolation methods for exosomes**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Conventional isolation of exosomes** | | | | |
| **Methods** | **Advantages** | **Disadvantages** | **Clinical use** | **Ref.** |
| Ultracentrifugation | Widely used; high purity; protein and RNA components are not affected | Highly labour intensive; time-consuming; yields are typically low extensive training of personnel needed; expensive; inappropriate for the extraction of exosomes from a small amount of serum samples | Functional study of exosomes | [65,66] |
| Ultrafiltration | High yield; simple; less time-consuming; do not require the use of special equipment | Low purity, clogging of pores | Study of sample concentration; used in combination with other methods | [67] |
| Precipitation | Widely used; economical | Co-isolation of non-EV particles | For studies with very low purity requirements that do not require omics studies | [68] |
| Size exclusion chromatography, OR, and gel filtration | Fast, reliable, and inexpensive; maintain the biological activity and integrity of exosomes; high purity | Nanoscale contaminants like lipoproteins; extensive laboratory equipment requirements | Suitable for exosome research in those requiring high purity, omics, and large volume samples | [69] |
| Immunoaffinity capture | Convenient; not affected by exosome size; no need for expensive instruments | Expensive; low capacity; low yields | Suitable for the Separation of specific exosome subgroups | [70] |
| Emerging isolation methods | | | | |
| Stirred ultrafltration | Do not rely on equipment; less time consuming; reduces the destruction of exosomes during the process | Moderate purity of isolated exosomes; loss of exosomes during the process | Isolating exosomes from culture supernatant of bone marrow mesenchymal stem cells | [71] |
| ExoTIC **(exosome total isolation chip)** | Simple, easy-to-use, modular, and facilitates high-yield and high-purity EV isolation from biofluids | Special equipment requirements; lack of tests on clinical samples | Efficiently isolate EVs from small sample volumes; EV-based clinical testing from fingerprick quantities (10-100 μL) of blood | [72,73] |
| 3D ZnO Nanoarrays | Multifunction; high sensitivity; downstream analysis is possible; enhance the capture of exosomes at a high flow rate | Relatively expensive | Widely used in biosensing and analysis aspects, powerful tools for effective purification and molecular analysis of exosome | [74,75] |
| Nano plasmon-enhanced scattering | Rapid, high-throughput, sensitive, and specifc method for the detection of exosomes from trace samples depending on the amount of scatter area, based on calculation of the proportion of the area that contains scattered light | High reagent cost; complex statistical tools; low capacity | Uses antibodies against the cellular markers CD81, CD63, and CD9, which are enriched on most exosome membranes | [76] |

SEC: Size exclusion chromatography; EV: Extracellular vesicle.